O
Orogen Therapeutics uses proprietary, AI-enabled DNA-encoded library (DEL) technology to identify novel small-molecule chemical matter against drug targets. The platform integrates DEL screening with massive chemical diversity and computation to generate enriched hit yields. The company focuses on developing oral small molecule medicines, particularly targeting cytokine pathways for immuno-inflammatory disorders.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Orogen Therapeutics uses proprietary, AI-enabled DNA-encoded library (DEL) technology to identify novel small-molecule chemical matter against drug targets. The platform integrates DEL screening with massive chemical diversity and computation to generate enriched hit yields. The company focuses on developing oral small molecule medicines, particularly targeting cytokine pathways for immuno-inflammatory disorders.